Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...

詳細記述

保存先:
書誌詳細
出版年:Int J Cancer
主要な著者: Groenendijk, Floris H, Mellema, Wouter W, van der Burg, Eline, Schut, Eva, Hauptmann, Michael, Horlings, Hugo M, Willems, Stefan M, van den Heuvel, Michel M, Jonkers, Jos, Smit, Egbert F, Bernards, René
フォーマット: Artigo
言語:Inglês
出版事項: Blackwell Publishing Ltd 2015
主題:
Cancer Therapy
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/
https://ncbi.nlm.nih.gov/pubmed/25080865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料